Molecular Physiology

Molecular Physiology Indian Medical PG Question 1: Km value is defined as:

• A. Substrate concentration at Vmax/2 (Correct Answer)
• B. Substrate concentration at which reaction rate is maximum
• C. Substrate concentration at Vmax
• D. Substrate concentration at which enzyme activity is optimal

Molecular Physiology Explanation: ***Substrate concentration at Vmax/2*** - The **Michaelis constant (Km)** is defined as the **substrate concentration** at which the reaction velocity is **half of the maximum velocity (Vmax/2)**. - It reflects the **affinity of an enzyme for its substrate**; a lower Km indicates higher affinity. *Substrate concentration at which reaction rate is maximum* - The **maximum reaction rate (Vmax)** is achieved when the enzyme is **saturated with substrate**, meaning all active sites are occupied. - Km specifically refers to the substrate concentration needed to reach **half of this maximum rate**, not the maximum rate itself. *Substrate concentration at Vmax* - At **Vmax**, the enzyme is fully saturated with substrate, and the reaction rate cannot increase further by adding more substrate. - The **Km value** is a measure related to the **efficiency of substrate binding** at conditions below saturation, specifically at half Vmax. *Substrate concentration at which enzyme activity is optimal* - **Optimal enzyme activity** is generally influenced by factors such as **pH and temperature**, which affect the enzyme's structure and catalytic efficiency. - Km is specifically related to the **substrate concentration** required to achieve a specific reaction rate, not the overall optimal environmental conditions for the enzyme.

Molecular Physiology Indian Medical PG Question 2: Which of the following statements is true regarding competitive reversible antagonism?

• A. ED50 remains unchanged in competitive reversible antagonism.
• B. Efficacy and Vmax remain unchanged. (Correct Answer)
• C. Potency remains unchanged in the presence of a competitive antagonist.
• D. Affinity (Kd) remains unchanged in competitive reversible antagonism.

Molecular Physiology Explanation: ***Efficacy and Vmax remain unchanged.*** - In competitive reversible antagonism, the antagonist binds to the same receptor site as the agonist but can be overcome by increasing the agonist concentration [2]. This means the **maximum effect (efficacy or Vmax)** of the agonist can still be achieved, although a higher dose is needed [2]. - The antagonist does not alter the intrinsic ability of the agonist to produce a full response, only its **apparent affinity** for the receptor. - This is the hallmark of competitive reversible antagonism: **rightward shift of the dose-response curve with no change in maximum response** [2]. *Potency remains unchanged in the presence of a competitive antagonist.* - **Potency** is a measure of the amount of drug needed to produce a given effect (often defined by EC50 or ED50) [3]. - A competitive antagonist requires a **higher concentration of agonist** to achieve the same effect, thus **decreasing the apparent potency** of the agonist [4]. - The dose-response curve shifts to the right (parallel shift) [4]. *ED50 remains unchanged in competitive reversible antagonism.* - **ED50 (effective dose 50)** is the dose that produces 50% of the maximum effect. - Because competitive antagonists shift the dose-response curve to the right, a **higher ED50** is required to achieve 50% of the maximum effect in the presence of an antagonist [4]. *Affinity (Kd) remains unchanged in competitive reversible antagonism.* - The **dissociation constant (Kd)** represents the affinity of a drug for its receptor [1]. - In competitive reversible antagonism, the antagonist increases the **apparent Kd** of the agonist (reduces apparent affinity), requiring more agonist to achieve receptor occupancy. - The **intrinsic Kd** of the agonist doesn't change, but its apparent affinity is reduced due to competition with the antagonist.

Molecular Physiology Indian Medical PG Question 3: All of the following hormones have cell surface receptors except:

• A. Thyroxine (Correct Answer)
• B. Insulin
• C. Adrenalin
• D. Growth Hormone

Molecular Physiology Explanation: ***Thyroxine*** - **Thyroxine** (T4) is a **lipid-soluble thyroid hormone** that readily crosses the cell membrane to bind to **intracellular nuclear receptors** in the nucleus. - This binding leads to changes in gene expression, which then mediates its metabolic effects. - Unlike peptide hormones, thyroid hormones do not require cell surface receptors. *Insulin* - **Insulin** is a **peptide hormone** that binds to specific **cell surface receptors** (tyrosine kinase receptors) on target cells. - This binding initiates a signaling cascade that regulates glucose uptake and metabolism. *Adrenalin* - **Adrenalin** (epinephrine) is a **catecholamine hormone** that binds to **G protein-coupled receptors (GPCRs)** on the cell surface. - This binding triggers intracellular signaling pathways, leading to the "fight-or-flight" response. *Growth Hormone* - **Growth hormone** is a **protein hormone** that binds to **cell surface receptors** (cytokine receptors) on target cells. - This interaction activates the JAK-STAT signaling pathway, promoting growth and metabolism.

Molecular Physiology Indian Medical PG Question 4: Which of the following medications does not interact with warfarin?

• A. Barbiturate
• B. Oral contraceptive
• C. Cephalosporins
• D. Benzodiazepines (Correct Answer)

Molecular Physiology Explanation: ***Benzodiazepines*** - **Benzodiazepines** are generally considered safe to use with warfarin as they are extensively metabolized in the liver, but they do not typically alter the **cytochrome P450 enzymes** responsible for warfarin metabolism. - They also do not interfere with **vitamin K recycling** or **platelet function**, which are key mechanisms through which other drugs interact with warfarin. *Barbiturate* - **Barbiturates** are **potent inducers of hepatic enzymes**, particularly CYP2C9, which is responsible for metabolizing warfarin. - This enzyme induction leads to **increased warfarin metabolism**, reducing its anticoagulant effect and necessitating higher warfarin doses. *Oral contraceptive* - **Oral contraceptives** can **reduce the anticoagulant effect of warfarin** by inducing clotting factors or inhibiting warfarin metabolism. - This interaction can increase the risk of **thromboembolic events** in patients on warfarin. *Cephalosporins* - Certain **cephalosporins**, especially those with a **methylthiotetrazole (MTT) side chain** (e.g., Cefamandole, Cefoperazone, Moxalactam), can **inhibit vitamin K epoxide reductase**. - This inhibition leads to a **decrease in vitamin K-dependent clotting factors**, thus potentiating the anticoagulant effect of warfarin and increasing bleeding risk.

Molecular Physiology Indian Medical PG Question 5: Which of the following statements about Selective Estrogen Receptor Modulators (SERMs) is correct?

• A. Act as agonists on estrogen receptors.
• B. Some SERMs can act as both agonists and antagonists on estrogen receptors. (Correct Answer)
• C. Used to reduce the risk of hot flushes and thromboembolism.
• D. Act as antagonists on estrogen receptors.

Molecular Physiology Explanation: ***Some SERMs can act as both agonists and antagonists on estrogen receptors.*** - **SERMs** (Selective Estrogen Receptor Modulators) exert tissue-specific effects, meaning they can act as an **estrogen receptor agonist** in some tissues while acting as an **antagonist** in others. - This **selective mechanism** allows them to confer beneficial estrogenic effects where desired (e.g., bone) and anti-estrogenic effects where unwanted (e.g., breast tissue). *Act as agonists on estrogen receptors.* - This statement is incomplete because while some SERMs can act as **agonists** in certain tissues (e.g., affecting bone density), they are not pure agonists across all tissues. - Their defining characteristic is their **selective action**, exhibiting mixed agonist and antagonist effects depending on the tissue. *Used to reduce the risk of hot flushes and thromboembolism.* - SERMs like **tamoxifen** and **raloxifene** can actually **increase the risk** of both hot flushes and thromboembolism. - **Hot flushes** occur due to their **anti-estrogenic effects** on the hypothalamus, which disrupts thermoregulation. - **Thromboembolism** risk is increased due to their **estrogenic (agonist) effects** on hepatic synthesis of coagulation factors. *Act as antagonists on estrogen receptors.* - This statement is also incomplete because, while some SERMs exhibit **antagonist activity** in certain tissues (e.g., the breast), they simultaneously act as **agonists** in other tissues (e.g., bone or endometrium). - A pure antagonist would block estrogen receptors in all tissues, which is not the defining feature of SERMs.

Molecular Physiology Flashcard 1 of 3

Question: Osteo-_____ dissolve bone by secreting H+ and collagenases.

Answer: clasts

Molecular Physiology Flashcard 2 of 3

Question: cGMP stimulates _____, which dephosphorylates myosin and relaxes smooth muscle.

Answer: myosin-light-chain phosphatase

Molecular Physiology Flashcard 3 of 3

Question: _____ is a technique to record ion current flow through a single protein channel.

Answer: Patch-clamp